Picture of Adaptimmune Therapeutics logo

ADAP — Adaptimmune Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+22.6%
3m-9.25%
6m-45.98%
1yr-56.93%
Volume Change (%)
10d/3m-37.06%
Price vs... (%)
52w High-75.95%
50d MA+1.07%
200d MA-47.36%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-49.3%
Return on Equity-72.24%
Operating Margin-1876.62%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for ADAP

Keep an eye on the price momentum at Adaptimmune Therapeutics background image

Keep an eye on the price momentum at Adaptimmune Therapeutics

Anyone familiar with stock market screeners will know that shares in Adaptimmune Therapeutics (NSQ:ADAP) have been in an uptrend in recent months, with strong relative price strength on a 1-month, 6-month and 12-month basis.Knowing exa...

Will Adaptimmune Therapeutics's price keep soaring? background image

Will Adaptimmune Therapeutics's price keep soaring?

Studies by leading experts into the power of price momentum show that stocks with the strongest price trends tend to keep up the pace for anywhere up to one year. A big part of the reason for this is down to investor psychology.  With...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Adaptimmune Therapeutics EPS forecast chart

Profile Summary

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and have reported clinical responses (per RECIST 1.1) in seven solid tumor indications. Its platform enables to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors; Tumor Infiltrating Lymphocytes (TiLs) where a patient’s own T-cells are co-administered with its next generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its clinical trials include Spearhead-1 Phase II trial with afamitres gene autoleucel; Surpass Phase I Trial with ADP-A2M4CD8, and others.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
December 3rd, 2014
Public Since
May 6th, 2015
No. of Shareholders
27
No. of Employees
494
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
971,191,902

ADAP Share Price Performance

Upcoming Events for ADAP

Similar to ADAP

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email